Samsung Bio, Signs Contract for 22.5 Billion KRW Contract Manufacturing with US Pharmaceutical Company
[Asia Economy Reporter Moon Hyewon] Samsung Biologics announced on the 4th that it has signed a contract worth 22.5 billion KRW for the contract manufacturing of biopharmaceuticals with a US-based pharmaceutical company.
The contract accounts for 3.21% of recent sales revenue. The contract period is from December 18, 2018, to December 31, 2021.
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- Tragedy Strikes on Part-time Job Commute... Man in His 30s Arrested for Drunk Driving Death of Freshman College Student
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
The contracting party will be disclosed after December 31, 2023, due to business confidentiality reasons.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
